The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Abstract
OBJECTIVE: The first episode of psychotic illness is a key intervention point. The initial experience with medication can affect willingness to accept treatment. Further, relapse prevention is a treatment cornerstone during the first years of illness because active psychotic illness may affect lifetime outcomes. Thus, initial treatment of active symptoms and subsequent relapse prevention are central goals of pharmacotherapy. This study compared long-term effectiveness of risperidone versus haloperidol in first-episode psychosis patients. METHOD: First-episode psychosis patients (N=555, mean age=25.4 years) participated in a double-blind, randomized, controlled flexible-dose trial that compared risperidone (mean modal dose=3.3 mg) and haloperidol (mean modal dose=2.9 mg). The median treatment length was 206 days (maximum=1,514). RESULTS: Positive and Negative Syndrome Scale scores and Clinical Global Impression ratings improved significantly relative to baseline, with no significant differences between groups. Three-quarters of the patients achieved initial clinical improvement, defined as >20% reduction in total Positive and Negative Syndrome Scale score. However, among those who achieved clinical improvement, 42% of the risperidone group experienced a relapse compared with 55% of the haloperidol group. The median time to relapse was 466 days for risperidone-treated subjects and 205 days for those given haloperidol. These differences were statistically significant based on Kaplan-Meier survival analysis. Adverse effects distinguished the treatments: there were significantly more extrapyramidal signs and symptoms and adjunctive medication use in the haloperidol group and greater prolactin elevation in the risperidone group. There was less weight gain with haloperidol initially but no significant differences between groups at endpoint. CONCLUSIONS: Relatively low doses of antipsychotic drugs lead to significant symptom amelioration in the majority of first-episode psychosis patients. In the long term, risperidone prevents relapse in more patients and for a longer time and also induces less abnormal movements than haloperidol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Research Diagnoses for Tardive Dyskinesia
Kane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290040080014 · Cited by 937
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Csernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605
Leucht, S., Barnes, T. R. E., Kissling, W., Engel, R. R., Correll, C., & Kane, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1209 · Cited by 517
Predictors of Treatment Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D. G., Woerner, M. G., Alvir, J. M. J., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Bilder, R., Goldman, R., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.544 · Cited by 466
Lieberman, J. A., Tollefson, G., Tohen, M., Green, A. I., Gur, R. E., Kahn, R., McEvoy, J., Perkins, D., Sharma, T., Zipursky, R., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1396 · Cited by 404
Self-citationMcEvoy, J. P. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320063009 · Cited by 381
Gitlin, M., Nuechterlein, K., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1835 · Cited by 217
Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis
Sanger, T. M., Lieberman, J. A., Tohen, M., Grundy, S., Beasley, Jr., & Tollefson, G. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.79 · Cited by 215
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.12.1724 · Cited by 194
Gitlin, M., Nuechterlein, K., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2004) · FOCUS · doi:10.1176/foc.2.1.122 · Cited by 183
Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter Study
Emsley, R. A., & Risperidone Working Group (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033413 · Cited by 180
Self-citationSchizophrenia: A Follow-up Study of the Results of Five Forms of Treatment
May, P. R. A. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780320056006 · Cited by 166
Atypical antipsychotic drugs and long-term outcome in schizophrenia.
Weiden, P. J., Aquila, R., & Standard, J. (1996) · PubMed · Cited by 155
The Evaluation and Treatment of First-episode Psychosis
Sheitman, B., Lieberman, P., Lee, H., & Strauss, R. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.653 · Cited by 120
Lieberman, J. A., Sheitman, B., Chakos, M., et al. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199804001-00005 · Cited by 72
Rabinowitz, J., Bromet, E. J., & Davidson, M. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00322-5 · Cited by 31
Self-citation
Cited by
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Self-citationThe 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Metadata
- Authors
- Schooler, N., Rabinowitz, J., Davidson, M., Emsley, R., Harvey, P. D., Kopala, L., McGorry, P. D., Van Hove, I., Eerdekens, M., Swyzen, W., De Smedt, G., & the Early Psychosis Global Working Group
- Venue
- American Journal of Psychiatry
- Published
- 2005-05-01
- Volume
- 162
- Issue
- 5
- Pages
- 947-953
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2111883919
- Cited by
- 348
- References
- 24
- FWCI
- 20.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.